Claims for Patent: 5,490,987

Summary for Patent: 5,490,987

Title:	Tableting of colestipol hydrochloride
Abstract:	PCT No. PCT/US92/05066 Sec. 371 Date Dec. 30, 1993 Sec. 102(e) Date Dec. 30, 1993 PCT Filed Jun. 23, 1992 PCT Pub. No. WO93/00915 PCT Pub. Date Jan. 21, 1993.The present invention provides a novel formulation of matter and a novel process for making it. In particular, the present invention provides unique and novel 1000 mg tablets of Colestipol hydrochloride having the advantageous properties of hardness and low friability and a novel process for making such tablets.
Inventor(s):	Robert W. Shen, Jeffrey E. Price
Assignee:	Pharmacia and Upjohn Co
Application Number:	US08/175,412
Patent Claims:	1. A pharmaceutical tablet which comprises approximately 1000 mg of fine-milled colestipol hydrochloride, 10-200 mg of povidone, 1-50 mg of colloidal silicon dioxide and 1-30 mg of magnesium stearate, and which has the following physical characteristics: ______________________________________ Hardness: Greater than 40 SCU's Friability: 0-0.1%/15 minutes. ______________________________________ 2. The tablet of claim 1, which has the following additional characteristics: ______________________________________ Hardness: 40-75 SCUs Tablet Weight: 1017-1079 mg Disintegration Time: Less than 5 minutes Thickness: 5.08-8.64 mm (0.200-0.340 inch). ______________________________________ 3. The tablet of claim 2, comprising approximately 1000 mg colestipol hydrochloride, wherein the tablet weight is approximately 1048 mg, the hardness is 40-50 SCUs, and the thickness is 8.13-8.64 mm (0.320-0.340 inch). 4. The tablet of claim 1, which comprises approximately 40 mg povidone. 5. The tablet of claim 1 comprising 40-50 mg povidone, 5-10 mg colloidal silicon dioxide, and 2.5-3.5 mg magnesium stearate. 6. The tablet of claim 5, comprising approximately 40 mg povidone, approximately 5 mg colloidal silicon dioxide and approximately 3 mg magnesium stearate. 7. The tablet of claim 1, which further has a seal coating comprising cellulose acetate phthalate and triacetin in the coating. 8. The tablet of claim 7, comprising 2-100 mg cellulose acetate phthalate and 0.5-20 mg triacetin in the coating. 9. The tablet of claim 8, comprising approximately 15.6 mg cellulose acetate phthalate and approximately 3.12 mg triacetin in the coating. 10. The tablet of claim 7, which further has a clear coating comprising hydroxypropyl methylcellulose and triacetin in the coating. 11. The tablet of claim 10, comprising 5-100 mg hydroxypropyl methylcellulose 2910 E5 Premium USP 5 CPS, 5-100 mg hydroxypropyl methylcellulose 2910 USP 15 CPS and 2-80 mg triacetin in the coating. 12. The tablet of claim 11, comprising approximately 30 mg hydroxypropyl methylcellulose 2910 E5 Premium USP 5 CPS, approximately 30 mg hydroxypropyl methylcellulose 2910 USP 15 CPS and approximately 12 mg triacetin in the coating. 13. The tablet of claim 12, which has the following physical characteristics: ______________________________________ Tablet Weight: 1100-1230 mg Disintegration Time: Less than 30 minutes Hardness: Greater than 60 SCUs Thickness: 5.08-10.16 mm (0.200-0.400 inch) Friability: 0-0.1%/15 minutes. ______________________________________ 14. The tablet of claim 13, wherein the tablet weight is approximately 1138 mg, the hardness is 60-80 SCUs, the thickness is approximately 9.52 mm (0.375 inch) and the friability is approximately 0%/15 minutes. 15. The tablet of claim 1, obtainable by adding 10-200 mg. providone to a dewatered slurry of fine-milled colestipol hydrochloride; drying the resultant mixture; deaggregating the dried material; adding 1-50 mg. of colloidal silicon dioxide and 1-30 mg. of magnesium stearate to the deaggregated material; and compressing the resultant mixture into a tablet. 16. A process for preparing the tablet of claim 1, which comprises the steps of adding 10-200 mg. providone to a dewatered slurry of fine-milled colestipol hydrochloride; drying the resultant mixture; deaggregating the dried material; adding 1-50 mg. of colloidal silicon dioxide and 1-30 mg of magnesium stearate to the deaggregated material; and compressing the resultant mixture into a tablet. 17. The process of claim 16 wherein the resultant mixture is compressed into a tablet using 8,000-10,000 lbs. compressional force.